London-listed AstraZeneca said on Monday it would make an upfront payment of $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a newer class of treatments called antibody drug conjugates (ADC).
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
No comments:
Post a Comment